High aldehyde dehydrogenase activity at diagnosis predicts relapse in patients with t(8;21) acute myeloid leukemia
| العنوان: | High aldehyde dehydrogenase activity at diagnosis predicts relapse in patients with t(8;21) acute myeloid leukemia |
|---|---|
| المؤلفون: | Yan Chang, Ya-Zhe Wang, Yan-Rong Liu, Yan-Huan Zhang, Xiao-Hui Zhang, Ya-Zhen Qin, Wen-Min Chen, Kai-Yan Liu, Feng-Ting Dao, Qian Jiang, Xiao-Jun Huang, Lu Yang |
| المصدر: | Cancer Medicine, Vol 8, Iss 12, Pp 5459-5467 (2019) Cancer Medicine |
| بيانات النشر: | Wiley, 2019. |
| سنة النشر: | 2019 |
| مصطلحات موضوعية: | Male, 0301 basic medicine, Cancer Research, Neoplasm, Residual, t(8, 21) acute myeloid leukemia, Chromosomes, Human, Pair 21, CD34, Aldehyde dehydrogenase, CD38, Transcript level, Gastroenterology, Translocation, Genetic, RUNX1 Translocation Partner 1 Protein, 0302 clinical medicine, hemic and lymphatic diseases, Child, Original Research, relapse, biology, medicine.diagnostic_test, Myeloid leukemia, Middle Aged, Prognosis, lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens, Leukemia, Myeloid, Acute, Oncology, Child, Preschool, 030220 oncology & carcinogenesis, Core Binding Factor Alpha 2 Subunit, Female, Chromosomes, Human, Pair 8, Adult, medicine.medical_specialty, Adolescent, RUNX1‐RUNX1T1, lcsh:RC254-282, Flow cytometry, Young Adult, 03 medical and health sciences, aldehyde dehydrogenase, Internal medicine, medicine, Humans, Radiology, Nuclear Medicine and imaging, In patient, Aged, business.industry, flow cytometry, Clinical Cancer Research, Survival Analysis, Minimal residual disease, body regions, 030104 developmental biology, Multivariate Analysis, minimal residual disease, biology.protein, Neoplasm Recurrence, Local, business |
| الوصف: | Acute myeloid leukemia (AML) with t(8;21) is a heterogeneous disease. Although the detection of minimal residual disease (MRD), which is indicated by RUNX1‐RUNX1T1 transcript levels, plays a key role in directing treatment, risk stratification needs to be improved, and other markers need to be assessed. A total of 66 t(8;21) AML patients were tested for aldehyde dehydrogenase (ALDH) activity by flow cytometry at diagnosis, and 52 patients were followed up for a median of 20 (1‐34) months. The median percentage of CD34+ALDH+, CD34+CD38‐ALDH+, and CD34+CD38+ALDH+ cells among nucleated cells were 0.028%, 0.012%, and 0.0070%, respectively. The CD34+ALDH+‐H, CD34+CD38‐ALDH+‐H, and CD34+CD38+ALDH+‐H statuses (the percentage of cells that were higher than the individual cutoffs) were all significantly associated with a lower 2‐year relapse‐free survival (RFS) rate in both the whole cohort and adult patients (P = .015, .016, and .049; P = .014, .018, and .032). Patients with ALDH status at diagnosis may improve MRD‐based risk stratification in t(8;21) AML, and concurrent high levels of CD34 + ALDH+ at diagnosis and MRD predict relapse. |
| تدمد: | 2045-7634 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::55995ba593c6ccb574624ac9b7ef5fafTest https://doi.org/10.1002/cam4.2422Test |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....55995ba593c6ccb574624ac9b7ef5faf |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 20457634 |
|---|